[O-46] Oral Session 46

[O-46-1] Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified ASOs in ALS mice

Toshihide Takeuchi^1,3, Kazuhiro Maeta³, Ding Xin^2,3, Yukako Oe³, Akiko Takeda^2,3, Seiichi Nagano³, Tsuyoshi Fujihara⁴, Seiji Matsuda⁴, Shinsuke Ishigaki⁵, Kentaro Sahashi⁵, Eiko Minakawa⁶, Hideki Mochizuki³, Masahiro Neya⁴, Gen Sobue⁵, Yoshitaka Nagai^1,2,3 (1.Life Science Research Institute, Kindai University, Japan, 2.Kindai University Faculty of Medicine, Japan, 3.Osaka University Graduate School of Medicine, Japan, 4.KNC Laboratories Co., Ltd., Japan, 5.Nagoya University Graduate School of Medicine, Japan, 6.National Institute of Neuroscience, NCNP, Japan)